Genmab A/S (GEN.CO) Announces New Phase 3 Study Of Daratumumab In Multiple Myeloma & Improves 2014 Financial Guidance
5/1/2014 4:23:57 PM
Copenhagen, Denmark; May 1, 2014 – Genmab A/S (OMX: GEN) announced today that its partner, Janssen Biotech, Inc. (“Janssen”) will start a Phase III study of daratumumab in relapsed or refractory multiple myeloma. The study will compare daratumumab in combination with bortezomib and dexamethasone to bortezomib and dexamethasone alone.
Help employers find you! Check out all the jobs and post your resume.
comments powered by